ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor with Best-in-class Properties, Demonstrates Combination Synergy with AR Pathway Inhibitors in Prostate Cancer Models
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined